News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,055 Results
Type
Article (39195)
Company Profile (284)
Press Release (648576)
Section
Business (204093)
Career Advice (1994)
Deals (35406)
Drug Delivery (89)
Drug Development (80929)
Employer Resources (168)
FDA (16119)
Job Trends (14815)
News (344966)
Policy (32477)
Tag
Academia (2538)
Alliances (49199)
Alzheimer's disease (1250)
Approvals (16055)
Artificial intelligence (143)
Bankruptcy (352)
Best Places to Work (11576)
Biotechnology (202)
Breast cancer (186)
Cancer (1323)
Cardiovascular disease (106)
Career advice (1662)
Cell therapy (269)
Clinical research (64662)
Collaboration (442)
Compensation (245)
COVID-19 (2540)
C-suite (106)
Data (1360)
Diabetes (163)
Diagnostics (6170)
Earnings (84955)
Employer resources (146)
Events (110089)
Executive appointments (365)
FDA (16748)
Funding (408)
Gene therapy (192)
GLP-1 (590)
Government (4333)
Healthcare (18709)
Infectious disease (2629)
Inflammatory bowel disease (110)
Interviews (309)
IPO (16341)
Job creations (3628)
Job search strategy (1418)
Layoffs (416)
Legal (7863)
Lung cancer (186)
Manufacturing (194)
Medical device (13240)
Medtech (13245)
Mergers & acquisitions (19197)
Metabolic disorders (431)
Neuroscience (1561)
NextGen Class of 2024 (6508)
Non-profit (4469)
Northern California (1638)
Obesity (250)
Opinion (180)
Patents (114)
People (56463)
Phase I (20113)
Phase II (28477)
Phase III (21234)
Pipeline (503)
Postmarket research (2563)
Preclinical (8546)
Radiopharmaceuticals (236)
Rare diseases (252)
Real estate (5894)
Regulatory (21644)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1423)
Startups (3565)
United States (14741)
Vaccines (561)
Weight loss (175)
Date
Today (92)
Last 7 days (677)
Last 30 days (2731)
Last 365 days (35346)
2024 (34455)
2023 (40117)
2022 (51227)
2021 (55762)
2020 (54142)
2019 (46584)
2018 (35071)
2017 (32160)
2016 (31528)
2015 (37610)
2014 (31354)
2013 (26388)
2012 (28593)
2011 (29289)
2010 (27360)
Location
Africa (715)
Arizona (194)
Asia (37285)
Australia (6085)
California (3686)
Canada (1410)
China (290)
Colorado (167)
Connecticut (170)
Europe (79909)
Florida (513)
Georgia (130)
Illinois (372)
Indiana (218)
Kansas (96)
Maryland (614)
Massachusetts (2881)
Michigan (169)
Minnesota (285)
New Jersey (1062)
New York (1047)
North Carolina (734)
Northern California (1638)
Ohio (144)
Pennsylvania (901)
South America (1092)
Southern California (1423)
Texas (530)
Utah (105)
Washington State (392)
688,055 Results for "amber ophthalmics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
Amber Therapeutics, a UK-based medical technology company developing a breakthrough adaptive neuromodulation therapy to treat mixed urinary incontinence, announces the successful closing of its Series A financing raising a total of $100 million from leading healthcare and technology investors in the US and UK.
June 10, 2024
·
5 min read
Amber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinence
Amber Therapeutics (‘Amber’ or the ‘Company’), an innovative medical technology company developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system, announces the presentation of the first data from its AURA-2 (Augmenting Urinary Reflex Activity) first-in-human study evaluating Amber-UI.
February 27, 2024
·
5 min read
Drug Development
Amber Ophthalmics Announces First Patient Enrolled in NEXPEDE-1, a Phase 2/3 Clinical Trial Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defects
Amber Ophthalmics, Inc. (Amber) , a privately held, clinical stage biopharmaceutical company, announced today that Dr. Mark S. Gorovoy from Gorovoy M.D. Eye Specialists has enrolled the first patient in the AMB-01-006 (NEXPEDE-1) study.
August 18, 2023
·
2 min read
Press Releases
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines
December 12, 2024
·
4 min read
Deals
Amber Tx acquires Bioinduction Limited and its Picostim DyNeuMo platform, on which Amber’s closed-loop neuromodulation therapy for mixed urinary incontinence is being developed
Amber Therapeutics announces it has acquired Bioinduction Limited and its Picostim DyNeuMo neuromodulation therapy platform.
September 5, 2023
·
4 min read
Press Releases
Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases
December 9, 2024
·
3 min read
Press Releases
Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC)
August 19, 2024
·
2 min read
Pharm Country
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved products.
April 25, 2024
·
10 min read
Press Releases
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Ocular Surgery Relief and Recovery
August 5, 2024
·
3 min read
Pharm Country
Vyluma Meets with FDA on Atropine Sulfate Ophthalmic Solution 0.01% Under Development to Treat Pediatric MyopiaVyluma Discusses Response to FDA’s Questions and Clarifies Regulatory Pathway for its 505(b)(2) NDA
Vyluma, Inc. (“Vyluma”), a clinical stage pharmaceutical company is focused on the development of ophthalmic treatments for disease states with limited treatment options.
June 18, 2024
·
5 min read
1 of 68,806
Next
